Literature DB >> 25650364

Routine second-look after surgical treatment of colonic peritoneal carcinomatosis.

J B Delhorme1, E Triki2, B Romain2, N Meyer3, S Rohr2, C Brigand2.   

Abstract

BACKGROUND: Surgical procedures that combine both complete cytoreductive surgery (CCRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have improved the survival of patients with peritoneal carcinomatosis (PC). Current imaging and laboratory investigations are not very useful to diagnose PC. This prospective study sought to determine the usefulness of routine second-look surgery (RSLS) combined with HIPEC in the diagnosis and treatment of patients with PC at high-risk for recurrence.
METHODS: From 2007 to 2011, RSLS was performed on 14 patients who had undergone a complete initial oncological resection for synchronous colonic PC and/or ovarian metastasis with PC discovered during primary colon cancer surgery after a course of 12 cycles of intravenous chemotherapy, eventually associated with HIPEC.
RESULTS: Pathology confirmed PC in 71% of patients during RSLS, with a median peritoneal carcinomatosis index (PCI) of 10. There was no post-operative mortality, while 7% of patients exhibited Dindo Grade III-IV complications. The 2-year overall survival and disease-free survival rates were 91% and 38%, respectively. Following RSLS and CCRS, peritoneal recurrence was observed in only 8% of patients who had undergone HIPEC.
CONCLUSION: RSLS combined with HIPEC after initial resection of synchronous colonic PC allows diagnosis and treatment of low-score PC, with limited post-operative complications and increased overall survival rates.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Colon cancer; HIPEC; Peritoneal carcinomatosis; Second-look surgery

Mesh:

Substances:

Year:  2015        PMID: 25650364     DOI: 10.1016/j.jviscsurg.2015.01.002

Source DB:  PubMed          Journal:  J Visc Surg        ISSN: 1878-7886            Impact factor:   2.043


  8 in total

Review 1.  Peritoneal Metastases from Gastrointestinal Cancer.

Authors:  Paul H Sugarbaker
Journal:  Curr Oncol Rep       Date:  2018-06-08       Impact factor: 5.075

2.  Prevention and Treatment of Peritoneal Metastases: a Comprehensive Review.

Authors:  Paul H Sugarbaker
Journal:  Indian J Surg Oncol       Date:  2019-01-03

3.  Second-look Surgery for Appendiceal High Grade and Colorectal Cancers Following Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Authors:  Mohammad Breakeit; Daniel Liu; Adrian Cheng; Hyerim Suh; Shoma Barat; Amer Matar; Nayef Alzahrani; David L Morris
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

4.  Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with improved perioperative outcomes: a single-center early experience propensity-matched analysis.

Authors:  Tali Shaltiel; Daniel Solomon; Eric R Pletcher; Benjamin J Golas; Deepa R Magge; Umut Sarpel; Daniel M Labow; Noah A Cohen
Journal:  Surg Endosc       Date:  2022-01-26       Impact factor: 3.453

Review 5.  [Surgical treatment of peritoneal metastases of colorectal cancer].

Authors:  S Schüle; H Mothes; U Settmacher; J Zanow
Journal:  Chirurg       Date:  2018-09       Impact factor: 0.955

6.  Individualized multimodal treatment strategy for metastatic rectal adenocarcinoma: Case report.

Authors:  Helena Magalhães; Mário Fontes-Sousa; Manuel Fernandes; Manuela Machado
Journal:  Porto Biomed J       Date:  2018-07-03

7.  Results of systematic second-look surgery plus hipec in perforated or pt4 colon cancer. Case series.

Authors:  Ángel Serrano Del Moral; Estíbalitz Pérez Viejo; Israel Manzanedo Romero; Fernando Pereira Pérez
Journal:  Ann Med Surg (Lond)       Date:  2021-01-24

8.  Early postoperative outcomes of staging laparoscopy for peritoneal metastases with or without pressurized intra-peritoneal aerosol chemotherapy (PIPAC).

Authors:  Hugo Teixeira Farinha; Daphné Mattille; Styliani Mantziari; Nicolas Demartines; Martin Hübner
Journal:  BMC Surg       Date:  2022-03-30       Impact factor: 2.102

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.